Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-06-05
2007-06-05
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S091330
Reexamination Certificate
active
10688100
ABSTRACT:
One approach to treating individuals infected with HIV-1 is to administer to such individuals compounds that directly interfere with and intervene in the machinery by which HIV-1 replicates itself within human cells. Although the specific role of HIV-1 viral protein Vif in the viral life cycle is not known, the vif gene is essential for the pathogenic replication of lentiviruses in vivo. The present invention relates to a method for treating an individual exposed to or infected with HIV-1. Individuals identified as being exposed to or infected by HIV-1 are administered a therapeutically effective amount of one or more compounds that inhibit or prevent replication of said HIV-1 by interfering with the replicative or other essential functions of HIV-1 viral protein Vif by interactively blocking the multimerization domain of Vif, thereby preventing multimerization of Vif protein, which is important for Vif function in the lentivirus life cycle. In preferred embodiments, the compound or compounds that interactively block the multimerization domain of Vif are Vif antagonists. Pharmaceutical compositions comprising these compounds are also disclosed.
REFERENCES:
patent: 0330359 (1989-08-01), None
patent: 0959136 (1999-11-01), None
patent: WO95/05851 (1995-03-01), None
patent: WO98/52970 (1998-11-01), None
patent: WO02/081504 (2002-10-01), None
Choppin J et al.: “Analysis of Physical Interactions between Peptides and HLA Molecules and Application to the Detection of Human Immunodeficiency Virus 1 Antigenic Peptides”, Journal of Experimental Medicine, vol. 172, Sep. 1990; pp. 889-899.
Friedler et al.: “Peptides Derived from HIV-1 Vif: A Non-substrate Based Novel Type of HIV-1 Protease Inhibitors”, Journal of Molecular Biology, vol. 287, 1999, pp. 93-101.
Jin X et al.: “Identification of Subdominant Cytotosis T Lymphocyte Epitopes Encoded by Autologous HIV Type 1 Sequences, Using Dendritic Cell Stimulation and Computer-Drived Algorithm” AIDS Research and Human Retroviruses, vol. 16, No. 1, Jan. 2000.
Yang S et al.: “The Multimerization of Human Immunodeficiency Virus Type 1 Vif Protein”, The Journal of Biological Chemistry, vol. 276, No. 7, Nov. 8, 2000, pp. 4889-4893.
Zhang, Hui et al.: “Human Immunodeficiency Virus Type 1 Vif Protein Is an Integral Component of an MrNP Complex of Viral RNA and Could Be Involved in the Viral RNA Folding and Packaging Process”, Journal of Virology, Sep. 2000, p. 8252-8261.
Guy et al.: “A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein”, Journal of Virology, vol. 65, No. 3 (Mar. 1991), pp. 1325-1331 (abstract only).
Yang, et al.: “Mitogen-activated Protein Kinase Phosphorylates and Regulates the HIV-1 Vif Protein”,The Journal of Biological Chemistry, vol. 273, No. 45, Issue of Nov. 6, 1998 pp. 29879-29887.
Simon, James H.M., et al.: “Mutational Analysis of the Human Immunodeficiency Virus Type 1 Vif Protein”,Journal of Virology, vol. 73, No. 4, Apr. 1999, pp. 2675-2681.
Huvent, Isabelle, et al.: “Interaction and co-encapsidation of human immunodeficiency virus type 1 Gag and Vif recombinant proteins”Journal of General Virology, vol. 79, pp. 1069-1081 (1998).
Goncalves, Joao, et al.: “Biological Activity of Human Immunodeficiency Virus Type 1 Vif Requires Membrane Targeting by C-Terminal Basic Domains”,Journal of Virology, vol. 69, No. 11, Nov. 1995, pp. 7196-7204.
Bouyac, Michele, et al.: “Human Immunodeficiency Virus Type 1 Vif Protein Binds to the Pr55GagPrecursor”,Journal of Virology, vol. 71, No. 12, Dec. 1997, pp. 9358-9365.
Pomerantz Roger J.
Yang Bin
Zhang Hui
Drinker Biddle & Reath LLP
Monaco Daniel A.
Salimi Ali R.
Thomas Jefferson University
LandOfFree
Multimerization of HIV-1 Vif protein as a therapeutic target does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multimerization of HIV-1 Vif protein as a therapeutic target, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multimerization of HIV-1 Vif protein as a therapeutic target will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3821989